Raw incidence of grade 3-4 adverse events according to treatment phase (intention-to-treat analysis)
| . | PAD (n = 102) . | PAD-MEL100-ASCT (n = 102) . | PAD-MEL100-ASCT-LP (n = 102) . | PAD-MEL100-ASCT-LP-L (n = 102) . |
|---|---|---|---|---|
| Hematological | ||||
| Anemia | 3 (3%) | 16 (16%) | 16 (16%) | 16 (16%) |
| Thrombocytopenia | 17 (17%) | 89 (87%) | 93 (91%) | 93 (91%) |
| Neutropenia | 10 (10%) | 90 (88%) | 91 (89%) | 92 (90%) |
| Nonhematological | ||||
| Infections | 17 (17%) | 30 (29%) | 33 (32%) | 34 (33%) |
| Peripheral neuropathy | 16 (16%) | 16 (16%) | 16 (16%) | 18 (18%) |
| Venous thromboembolism | 5 (5%) | 5 (5%) | 7 (7%) | 7 (7%) |
| Gastrointestinal | 10 (10%) | 14 (14%) | 15 (15%) | 18 (18%) |
| Dermatological | 2 (2%) | 1 (1%) | 6 (6%) | 10 (10%) |
| . | PAD (n = 102) . | PAD-MEL100-ASCT (n = 102) . | PAD-MEL100-ASCT-LP (n = 102) . | PAD-MEL100-ASCT-LP-L (n = 102) . |
|---|---|---|---|---|
| Hematological | ||||
| Anemia | 3 (3%) | 16 (16%) | 16 (16%) | 16 (16%) |
| Thrombocytopenia | 17 (17%) | 89 (87%) | 93 (91%) | 93 (91%) |
| Neutropenia | 10 (10%) | 90 (88%) | 91 (89%) | 92 (90%) |
| Nonhematological | ||||
| Infections | 17 (17%) | 30 (29%) | 33 (32%) | 34 (33%) |
| Peripheral neuropathy | 16 (16%) | 16 (16%) | 16 (16%) | 18 (18%) |
| Venous thromboembolism | 5 (5%) | 5 (5%) | 7 (7%) | 7 (7%) |
| Gastrointestinal | 10 (10%) | 14 (14%) | 15 (15%) | 18 (18%) |
| Dermatological | 2 (2%) | 1 (1%) | 6 (6%) | 10 (10%) |